Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen

US10946106B2 · kind B2 · utility

Assignee

• The Regents of the University of California · US

Inventors

• Bin Liu · Fishers, US
• Scott Bidlingmaier · San Francisco, US
• Yang Su · South San Francisco, US

Key dates

• Filing date: Nov 29, 2016
• Grant date: Mar 16, 2021
• Expiry date: Jul 26, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention provides antibodies directed against a highly specific and previously unrecognized marker for cancerous cells. In certain embodiments an isolated antibody or fragment thereof that specifically binds human placentally expressed ALPP and/or ALPPL2, but not ALPL and ALPI that are expressed outside the placenta is provided as well as immunoconjugates comprising such antibodies.